Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Apr 17, 2013 4:37pm

213 Views

Post# 21267454

RE: BET Inhibitors - a slide show

Great find jdstox. It is noteworthy that this powerpoint is from GlaxoSmithKline. And in the final slide it also acknowledges Cellzome, a company that GSK acquired in 2012.

https://www.cabume.co.uk/medtech/new-spin-out-following-gsks-acquisition-of-cellzome.html

Coincidentally, at the upcoming Epigenetics in Drug Discovery conference in May, there are only 3 presentations that make mention of BET inhibitors. 1) An RVX presentation by Peter Young, 2) A GSK presentation by Olena Barbash, and 3) A Cellzome presentation by Antje Dittman.

https://www.gtcbio.com/conference/epigenetics-in-drug-discovery-agenda

Sounds like a great idea for GSK to buyout RVX and be the world leader in BET inhibitors, don't you think?

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity